WHAT THIS PAPER ADDS This is the first paper that calculates, based on data of a large cohort of arteriovenous access fistulae (AVF) operations and 10-year follow-up, the functional dialysis use of common types of AVF and comes to precise estimates of which strategy is most effective. The maturation time of AVF without interventions was accurately estimated. This guides planning of access and may serve as a benchmark to judge interventions to improve AVF maturation.
INTRODUCTION
Guidelines on vascular access for haemodialysis agree that arteriovenous fistulae (AVF) are the preferred form of access.
1,2 AVF are associated with better patient survival than other forms of access. 3, 4 The main disadvantage of AVF are the high primary failure rates (PFs) and that they are not immediately available for use. A maturation time of several weeks is needed to ensure safe cannulation without compromising the survival of the access. 5 Observed maturation times vary widely. 6, 7 The Dialysis Outcomes and Practice Patterns Study (DOPPS) showed that cannulation after surgery occurred within 8 weeks in 14% of AVF in the United States, in 45% in the United Kingdom, and in over 90% in Europe. 8 Furthermore, although there is agreement that AVF should be placed as distally as possible, there is discussion on which AVF is most appropriate for elderly people, considering the high primary failure rate of radiocephalic fistulae (RCAVF) compared with brachiocephalic fistulae (BCAVF) in this age group. 9e11 Primary failure rates, maturation times, 7 and AVF survival vary with the type of AVF and patient characteristics. 12, 13 Accurate contemporary data on maturation time and long-term AVF survival, which includes PF rates, are vital for vascular access planning. This study aims to estimate PF rates, maturation times of common AVF, and the long-term survival of AVF to inform strategic decision-making in access planning to achieve maximum benefit in terms of functional dialysis use.
METHODS
Retrospective analysis of two prospectively maintained databases of vascular access operations and dialysis sessions in a single Hospital Trust. The study period was from December 1, 2002 , to December 31, 2011 with follow-up until December 31, 2014. All operations and dates of operation were corroborated with the Hospital Episodes Statistics and electronic patient records. Additional information was sought from the home dialysis team, the vascular access coordinators, or the dialysis unit. We used a strict definition of functional dialysis use as a measurement for primary failure (PF) and maturation rates. A fistula was defined as mature if it was used for dialysis for six consecutive dialysis sessions with two needles, resulting in central venous catheter (CVC)-free dialysis. In a small minority of patients (2.8%) who had not started dialysis, an AVF was deemed mature if an experienced dialysis nurse considered that the AVF could be used for dialysis based on clinical examination. PF is defined as failure to provide dialysis for six consecutive sessions on two needles. An AVF was coded as PF if the pre-dialysis team considered that the AVF had failed in patients who had not started dialysis during the study period. Our PF definition includes immediate failure, early dialysis suitability failure, and late dialysis suitability failure. 12, 14 We did not use duplex ultrasound criteria to assess fistula maturation.
Maturation time was defined as the time from the date of operation to the date of the sixth consecutive dialysis session with two needles. This is when the CVC is removed, indicating the start of CVC-free dialysis. Maturation time was only estimated for patients already on dialysis on a CVC at the time of the AVF operation, as there are clinical and financial incentives to use the AVF as soon as it is mature in order to remove the CVC. 15 The time until the sixth needling date reflects the true maturation time of the AVF in only these patients, as it avoids confounding by indication, that is the time to needling in pre-dialysis patients, related to decline in renal function.
Cumulative patency was defined according to the North American Vascular Access Consortium criteria, as fistula survival from the operation date to the last needling date before the AVF was abandoned for a new form of access, irrespective of any interventions.
14 PF was included in the estimates of cumulative patency. The cumulative patency rates of the AVF with PF were set at 1 day, as accurate dates of failure were not available for those AVF. A revision, more proximal in the forearm, was not coded as a new AVF if the patient continued to dialyse on the AVF within three dialysis sessions. An elbow AVF above a forearm AVF was always coded as a new AVF and the forearm AVF as failed. Patients were censored at the last needling date if they died, moved away, underwent renal transplantation, or switched to peritoneal dialysis. To estimate total functional dialysis use the total time at risk of failure for all AVF was calculated, expressed as dialysis-person-years (py). This is the product of number of AVF operations in the group, and the total time each AVF was used for dialysis, per 100 AVF operations. Diabetes was coded as recorded on the dialysis database and the electronic patient records. The cause of chronic kidney disease (CKD) was coded as diabetic, vascular CKD (hypertensive or renovascular disease), autoimmune CKD (glomerulonephritis, vasculitis, antiglomerular basement membrane disease, etc.), post-renal CKD (obstructive urological causes), polycystic kidney disease, and other or unknown as per nephrology records.
Access planning protocol
The most distal site was chosen to create an AVF in order to preserve the maximum number of future access sites.
1,2
The "more distal rule" takes precedence in the unit over the "non-dominant arm rule". A BCAVF is made if all forearm sites in both arms are exhausted. Since August 31, 2004, ultrasound criteria have been used as part of a trial 16 and from October 1, 2007, ultrasound criteria were adopted routinely. An RCAVF was chosen if the radial artery was 2 mm or more and the forearm cephalic vein was 2 mm or more and in continuity to the elbow. A BCAVF was chosen if the brachial artery was 3 mm or more and an elbow vein was 3 mm or more. A BBAVF was made if the brachial artery was 3 mm or more and the basilic vein at the elbow was 3 mm or more. 16 The same criteria to select site of AVF was used for all age groups.
Statistical analysis
Comparisons of categorical data were made using chisquare tests. Continuous variables were analysed using the Student t-test or one-way ANOVA. Cumulative patency data were compared with life table methods and log-rank tests of survival function. Multivariate analysis of PF was done using logistic regression methods and multivariable survival analysis with Cox proportional hazard models. Automated stepwise regression was not used; a model that included age, sex, and type of AVF was used and variables added according to the univariate analysis. Variables were kept in the model if p < .05 on the likelihood ratio test. All statistical calculations were done with STATA 12 for Macintosh (STATA Corporation, TX, USA).
This study was a follow-up study using routinely collected data. No experimentation was performed and no patients were contacted outside their routine clinical care.
RESULTS

Study population
Altogether 1249 AVF operations were performed over the study period: 905 (72.5%) AVF were needled for dialysis and 344 (27.5%) AVF were not used. Of these 344 AVF that were not used, 273 had failed and 34 (2.7%) were clinically mature for dialysis but had not been used. A further 37 (3.0%) AVF had an unknown outcome, as no record of AVF failure and no record of dialysis use was made; 26 (2.1%) patients had died; one had a pre-emptive kidney transplant and 10 (0.8%) were lost to follow-up. These 37 AVF with unknown outcomes were excluded from analysis. Six (0.5%) non-standard AVF (1 ulnocephalic AVF, 2 ulnobasilic AVF, and 3 radiobasilic AVF) were also excluded ( Fig. 4 and Table 7 , electronic supplementary material). Most (96%) brachiobasilic transpositions (BBAVF) were one-stage procedures, and 92% of BBAVF were done under general anaesthesia. Local anaesthesia was used for 91% for radiocephalic AVF (RCAVF) and 93% of brachiocephalic AVF (BCAVF). Eighty-nine arteriovenous grafts were implanted in the study period.
Altogether, 1206 AVF were used for analysis; 689 (57%) RCAVF at the wrist or in the forearm; 383 (32%) BCAVF at the elbow and 134 (11%) BBAVF. The median age of the patients was 70 years (range 18e92 years), 58% were male, and 40% were diabetic. The main characteristics by type AVF is shown in Table 1 .
Primary failure
PF occurred in 280 (23%) of the 1206 AVF; 926 (77%) AVF had not failed; 895 AVF of these 926 AVF (97%) were used for six consecutive dialysis sessions and 31 AVF (3%) were mature, but dialysis had not started after a mean postoperative follow-up of 4.2 years (range 2.5e10 years). A total of 905 (75%) of AVF were used for dialysis, but 10 AVF failed to achieve functional dialysis use so were coded as PF, leading to a functional dialysis use in 895 of 1206 AVF (74%). CVC-free dialysis use occurred in 885 of 1206 AVF (73%). CVC-free dialysis use of the AVF was 71% in RCAVF, 78% in BCAVF, and 72% in BBAVF (p ¼ .057). Age at operation was not associated with PF: mean age (SD) for AVF with PF was 65.8 AE 15.4 years, and mean age for AVF that were used for dialysis was 66.3 AE 15.0 years (p ¼ .68). PF was significantly lower in BCAVF and in men. PF was higher in patients with vascular CKD (Table 2 ).
Multivariate analysis showed that female gender, non-BCAVF, and vascular CKD were independent predictors of PF. Age, diabetes, pre-dialysis state at time of fistula creation, previous AVF on the same side and operating surgeon were not associated with PF (Table 5 , electronic supplementary material).
Maturation time
Some 658 (55%) patients were on dialysis on a CVC at the time of AVF creation. These cases were used to calculate the maturation time, as the time to needling in these patients reflects the true AVF maturation and avoids confounding by indication, related to decline in renal function in pre-dialysis patients. Maturation time was estimated till the date of functional dialysis use on the fistula, reflecting the start of CVC-free dialysis. Maturation time was available for 449 of the 658 patients who were on dialysis when the AVF was created, 151 of the missing 159 cases were AVF with PF. We did not have an accurate maturation date, The numbers and percentages in the total column represent the numbers and percentages of the operations in subjects with the variable in the study population. The numbers and percentages in the used (for dialysis) and PF column represent the numbers of fistulae (AVF) with the variable in the used and PF groups. The numbers and percentages in the total column represent the number and percentages with that variable in the study population.
defined as the date of the sixth consecutive dialysis session with two needles for eight cases. The median maturation time was 10.3 weeks (IQR: 7.4e16.3 weeks). Percentiles of maturation times by type AVF are shown in Table 3 . Maturation times were statistically significantly different for different AVF; the BCAVF had shorter maturation times and BBAVF longer maturation times than RCAVF (Fig. 5 , electronic supplementary material) (KruskaleWallis chi square ¼ 13.4, 2 d.f., p ¼ .013). Women (median: 11.2 weeks; IQR 8.4e17.1 weeks) had longer maturation times than men (median 9.6 weeks; IQR 7.1e15 weeks; p ¼ .02). Age, diabetes (p ¼ .33) and vascular CKD (p ¼ .91) had no significant effect on maturation times. Only female gender was independently associated with maturation time in a regression model adjusted for type of AVF, age, sex, diabetes, vascular CKD, and previous AVF on the same side.
AVF survival
Cumulative patency, including PF, of RCAVF was significantly better than BCAVF and BBAVF (Fig. 1 , log-rank test: chi square ¼ 23.7, p < .003). The pre-dialysis state at the time of AVF creation was associated with significantly better AVF cumulative patency (Fig. 2 , log-rank test: chi square ¼ 24.7, p < .0001). Cumulative patency was worse in women if PF was included in the survival estimates (Fig. 3 , log-rank test: p ¼ .0005), but was not statistically significantly different if PF was excluded (log-rank test: chi square ¼ 2.6, p ¼ .11). Diabetes was associated with decreased AVF survival (logrank test: chi square ¼ 6.4, p ¼ .017). Cumulative patency was similar in patients with vascular CKD (log-rank test: chi square ¼ 0.02, p ¼ .88), or across the age categories (logrank test: chi square ¼ 5.6, p ¼ .13). Multivariate analysis using a Cox proportional hazard model (Table 6 , electronic supplementary material) showed that female gender, diabetes, and being on dialysis at AVF creation were independent predictors of decreased AVF survival. The proportionality assumption, tested with Schoenfeld residuals was valid (p ¼ .11). Functional dialysis time by type of AVF RCAVF had the best cumulative patency whereas BCAVF had the lowest PF risk and highest proportion of CVC-free use. The population benefit of RCAVF with BCAVF was compared by estimating total functional dialysis use, calculated as the product of total number of AVF operations and the time each AVF was used for dialysis, per 100 AVF operations. PF was included in the analysis by setting AVF cumulative patency at 1 day for all AVF with PF. All RCAVF operations resulted in a benefit of 7.8 dialysis-py or 3.5% (Table 4) . The RCAVF operations, in patients over 80, resulted in a population benefit of 25.7 dialysis-py, or 15%. An RCAVF results in greater CVC-free dialysis use if the AVF is used for longer than 1.5 years after its creation (Fig. 1) . The median postoperative survival of patients over 80 was 3 years; 75% lived more than 15 months, and only 10% died within 6 months of AVF operation. AVF operations in predialysis patients resulted in a population benefit of 27.2 dialysis-py or 13%.
DISCUSSION
This long-term study of all AVF operations in a single vascular unit, over 9 years, with a follow-up of 13 years, showed that BCAVFs had the lowest PF and the highest proportion of initial CVC-free dialysis use, but RCAVFs had the longest CVC-free dialysis use despite a higher PF rate.
The PF rate of AVF has improved in recent years. 12 A recent meta-analysis shows a PF of 23%, consistent with this study. 12 Others have also found that RCAVF and women have higher PF. 12, 13, 17 The reasons for higher PF in women are not clearly understood and are not explained by differences in vessel diameters. 18 The current results upper arm AVF are similar to the literature. 19, 20 AVF created before patients started dialysis had significantly better survival. The pre-dialysis state at AVF operation resulted in 13% more functional dialysis use. This is likely to be related to prior CVC use. 21 It cannot be ascertained whether the AVF was ipsilateral or contralateral to the CVC. However, most CVC are inserted as right-sided internal jugular lines. Left sided AVF had lower PF (19%) in patients on dialysis than right-sided AVF (28%, p ¼ .011). There is also evidence that more severe uraemia is associated with vascular endothelial changes that may impair fistula survival. 22 More importantly, the pre-dialysis state at the time of AVF creation is modifiable by better pre-dialysis organization and timely access planning. Accurate estimation of maturation time is vital for planning of AVF creation. Maturation times were statistically different for different AVF but the actual differences were fairly small and may not be clinically relevant. The median maturation time was 1 week shorter for BCAVF than RCAVF while the median maturation time of a BBAVF was 3 weeks longer. The longer maturation time of a BBAVF is not a reflection of multiple operations, as 96% were one-stage operations. It was shown that it takes approximately 10 weeks to have a 50% probability that an AVF is mature enough to be successfully used for CVC-free dialysis, and 16 weeks to have a 75% probability of CVC-free dialysis use. Therefore, an AVF should be created 3e4 months before the anticipated start of dialysis to increase the probability of long-term AVF survival. AVF survival was better for RCAVF than upper arm AVF. This could be a reflection of the easier needling of RCAVF or of the venous anatomy, as upperarm AVF have one venous outflow channel whereas RCAVF have multiple outflow channels. 23 Other reasons for late failure were rare; no RCAVF was ligated; three BCAVF and four BBAVF were ligated for arm swelling or infection. Ten procedures for steal syndrome were done on upper arm AVF.
The strength of our study is that this is a large, unselected cohort of all AVF created in a single vascular unit with long and comprehensive follow-up. Only 3% of patients were censored because of loss to follow-up. There was therefore little selection or observation bias. Our unit consists of seven vascular surgeons and four trainees. Three surgeons performed most vascular access operations during the study period (Table 7 , electronic supplementary material). The type of surgeon was not associated with outcome. This is consistent with a previous publication that trainees and consultants had similar outcomes provided there were standardized case selection, decision criteria, and operating procedures. 24 The limitations of this study are, firstly, there are no accurate data on reasons for AVF failure or accurate data on the number of interventions needed to achieve AVF maturation. PF due to early thrombosis cannot be distinguished from failure to mature. From a previous randomized trial, whose patients were included in this study, it is known that only 16% of the PF were caused by early thrombosis. 16 It is presumed that the majority of PF are due to failure to mature, which is in keeping with a large Scottish study. 25 There are no accurate data on the number of revisions needed to ensure maturation. Radiological interventions to improve maturation are not performed in the unit. Postoperative surveillance by clinical examination, which is 95% accurate, is used. 26 Eighty-three surgical Comparison of functional dialysis time, calculated as the dialysis-py in years, which is the product of total number of AVF operations and the time each AVF was used for dialysis, per 100 AVF operations, for RCAVF and BCAVF, by age group and dialysis state at operation. AVF with primary failure are included by setting the cumulative patency at 1 day for AVF with primary failure.
interventions were performed on the AVF in this study: only 27 (30%) were before the start of dialysis on that AVF, of which 23 were successful. The low number of pre-dialysis interventions on non-maturing AVF with high success rate suggests that there is room for improvement. The lower PF rate of BCAVF could be a reflection of vessel sizes but at present there are no data to confirm this. The major limitation of this study is that it is not randomized. Therefore, the fact that a patient requires an elbow AVF rather than a forearm AVF implies poorer vessels, which could affect long-term patency. 1, 2, 16 CONCLUSION RCAVF have higher PF, but better survival than upper arm AVF, and result in more functional dialysis use. RCAVF result in greater dialysis use if an AVF is used for more than 1.5 years. AVF created pre-dialysis have better survival. Vascular access planning should allow for a maturation time of 10 weeks, for a 50% probability, and 16 weeks for a 75% probability, that an AVF can be used. This study suggests that the best strategy in access planning is to create an RCAVF, irrespective of age, 4 months before the anticipated dialysis start.
